Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

Abstract Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real‐world settings. The ObservEr obs...

Full description

Bibliographic Details
Main Authors: Carmine Pinto, Francesca Di Fabio, Gerardo Rosati, Ivan R. Lolli, Enzo M. Ruggeri, Libero Ciuffreda, Daris Ferrari, Giovanni Lo Re, Giovanni Rosti, Paolo Tralongo, Raimondo Ferrara, Oscar Alabiso, Silvana Chiara, Giovanni P. Ianniello, Antonio Frassoldati, Domenico Bilancia, Giovanna A. Campanella, Carlo Signorelli, Patrizia Racca, Elena Benincasa, Maria Elena Stroppolo, Francesco Di Costanzo
Format: Article
Language:English
Published: Wiley 2016-11-01
Series:Cancer Medicine
Subjects:
Cetuximab
metastatic colorectal cancer
quality of life
skin reactions
Online Access:https://doi.org/10.1002/cam4.888

Internet

https://doi.org/10.1002/cam4.888

Similar Items